SCHEMBL24463571

SCHEMBL24463571

C#Cc1cc2ncn(C3CC3)c2cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.38
FGFR2 P21802 2/20 0.38
FGFR3 P22607 2/20 0.38
PGK1 P00558 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GAA P10253 1/20 0.37
ALDH1A1 P00352 2/20 0.34
CYP17A1 P05093 1/20 0.34
NPC1 O15118 1/20 0.34
HPGD P15428 1/20 0.34
DRD2 P14416 1/20 0.33
SLC6A4 P31645 1/20 0.33
CYP2C9 P11712 1/20 0.33
IDO1 P14902 1/20 0.33
KCNH2 Q12809 1/20 0.33
DAPK3 O43293 1/20 0.33
MAP4K4 O95819 1/20 0.33
PAK4 O96013 1/20 0.33
ABL1 P00519 1/20 0.33
LCK P06239 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24463262 0.83 IDO1 (0.40) FGFR1FGFR2FGFR3HSD17B10GAA
SCHEMBL30461533 0.81 FGFR1 (0.41) FGFR1FGFR2FGFR3PGK1HSD17B10
SCHEMBL24463344 0.81 FGFR1 (0.41) FGFR1FGFR2FGFR3PGK1HSD17B10
SCHEMBL28995813 0.80 FGFR1 (0.41) FGFR1FGFR2FGFR3HSD17B10GAA
SCHEMBL24463271 0.78 HSD17B10 (0.38) HSD17B10GAAALDH1A1NPC1HPGD
SCHEMBL30461540 0.78 HSD17B10 (0.38) HSD17B10GAAALDH1A1NPC1HPGD
SCHEMBL30263620 0.78 PGK1 (0.42) PGK1HSD17B10GAAALDH1A1NPC1
SCHEMBL26790657 0.78 PGK1 (0.42) PGK1HSD17B10GAAALDH1A1NPC1
SCHEMBL26791286 0.77 ABL1 (0.33) FGFR1DAPK3MAP4K4PAK4ABL1
SCHEMBL24463281 0.74 PGK1 (0.46) PGK1HSD17B10GAAALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374015-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KINNATE BIOPHARMA INC. 2023-11-23 US disclosed
US-20230374015-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KINNATE BIOPHARMA INC. 2023-11-23 US disclosed
US-11345681-B1 Inhibitors of fibroblast growth factor receptor kinases KINNATE BIOPHARMA INC. (US) 2022-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374015-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES FGFR1, FGFR2, FGFR3 FGFR1 1/4885FGFR2 2/4885FGFR3 3/4885
US-11345681-B1 Inhibitors of fibroblast growth factor receptor kinases FGFR1, FGFR2, FGFR3 FGFR1 1/4885FGFR2 2/4885FGFR3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.